Scientist

Evotec and Plectonic enter research collaboration to explore new generation of t-cell-engaging approaches for solid tumors. Sep 02, 2026, 02:04 ET * Collaboration aims to validate Evotec's proprietary BiTco costimulatory CD2 bispecifics platform in combination with Plectonic's logic-gated DNA-protein immunotherapy technology LOGIBODY(R) * BiTco designed to boost T cell activation by engaging a costimulatory signaling pathway * LOGIBODY(R) designed to enhance precision of T cell activation based on multispecific antigen signature HAMBURG, Germany and HALLBERGMOOS, Germany, Sept. 2, 2026 /PRNewswire/ - Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumors by combining Plectonic's programmable LOGIBODY(R) technology with Evotec's proprietary BiTco platform. Plectonic's LOGIBODY(R) technology engineers DNA-protein therapeutics designed to recognize tumors through a highly specific combination of tumor-associated antigens before engaging T cells. Unlike conventional T cell engagers, LOGIBODY(R) molecules require simultaneous binding to a predefined multi-antigen tumor signature to trigger T cell activation. This logic-gated approach represents a novel drug class aimed at improving treatment precision, reducing activation in healthy tissues and potentially broadening the therapeutic window. Evotec's BiTco platform is based on a proprietary, non-blocking CD2 antibody designed to provide an additional costimulatory signal to T cells, enhancing their activity and persistence within the tumor microenvironment. The antibody targets a unique CD2 epitope while preserving its natural interactions, enabling BiTco to strengthen T cell responses, enhance tumor cell killing mediated by T cell engagers, and delay T cell exhaustion. By combining highly selective tumor recognition and enhanced T-cell activation, the companies will explore whether their integrated technologies can improve both the precision and potency of T-cell-engaging approaches in solid tumors. Under the terms of the agreement, the collaboration will generate preclinical proof-of-concept data to evaluate the potential of this new generation of T-cell-engaging approaches. Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said: "T cell engagers have demonstrated significant promise in oncology in blood cancers, yet challenges remain in extending their clinical success to solid tumors, which represent approximately 90 percent of all cancers. Through this collaboration, we aim to evaluate the potential of combining our proprietary BiTco platform with Plectonic's LOGIBODY(R) technology and explore new strategies to enhance T cell engager activity in solid tumors. Our CD2-based co-stimulation approach is an ideal component for this effort or any TCE development strategy that seeks an effective source of T cell co-stimulation in the solid tumor setting." Dr. Klaus Wagenbauer, CEO and Founder of Plectonic Biotech, added: "This collaboration with Evotec highlights the broad potential and modularity of our LOGIBODY(R) technology to engineer logic-gated T-cell-engaging biologics and explore novel multi-specific designs. By combining our complementary technologies, we have the opportunity to enable highly precise and controlled immune activation at the tumor. Together, we look forward to investigating this next-generation modality and exploring new ways to address long-standing challenges in tumor selectivity and safety that have limited the effectiveness of T cell engagers in solid tumor indications." Plectonic has demonstrated the modularity of its LOGIBODY(R) technology in preclinical studies across both liquid and solid tumors, utilizing dual-targeting and co-stimulatory therapeutic strategies. Evotec recently published preclinical research on its BiTco platform, providing proof-of-concept for CD2-mediated T cell co-stimulation in combination with T cell engager approaches. About Plectonic Biotech Plectonic Biotech's new class of programmable DNA-protein therapeutics function as molecular logic gates to selectively direct the immune response to the tumor. By applying our modular LOGIBODY(R) platform, we are building a pipeline of multi-specific T-cell-engaging biologics designed to overcome off-target toxicity and exponentially improve the therapeutic impact of immunotherapies using clinically validated targets. Initially focused on hematologic malignancies, our approach is designed to deliver an unprecedented level of precision and control, broadening the therapeutic window and improving patient outcomes in both liquid and solid tumors. About Evotec SE Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec. Forward-looking statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Evotec Investor Relations and Media Contact Dr. Sarah Fakih EVP Head of Global Communications & Investor Relations [email protected] Plectonic Media Contact Trophic Communications Joe Rayne or Stephanie May [email protected] +49 171 185 5682 SOURCE Evotec SE

Evotec stock holds just above 52-week low as guidance cut weighs. Published on 09/01/2026 at 18:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Evotec stock is trading only slightly above its 52-week low as investors digest a sharply reduced full-year guidance and lingering restructuring risks around Project Horizon and recent voting-rights changes. Evotec (ISIN DE0005664809) stock is again trading close to its 52-week low, with the shares changing hands at around EUR 3.24 as of late August 2026, barely 0.9 percent above the EUR 3.19 floor set in July according to an Ad Hoc News market analysis dated September 1, 2026. Stock hovers near yearly floor. According to a detailed Ad Hoc News review, Evotec shares recently traded at about EUR 3.24, only slightly above the 52-week low of EUR 3.19 from July 2026, highlighting how little buffer remains for investors at current levels. The same analysis notes that Evotec's market capitalization stands at roughly EUR 595 million as of late August 2026, a level that underscores how a relatively small change in ownership stakes can materially move percentage holdings. Voting-rights notification adds ownership intrigue. On August 31, 2026, Evotec published a voting-rights notification under Article 40 of the German Securities Trading Act, revealing that a threshold was crossed on August 25, 2026; the company did not disclose which threshold or which shareholder was involved, but for a business valued at around EUR 595 million this type of stake change can be significant according to the Ad Hoc News coverage. The same report points out that Evotec's share price has fallen approximately 41 percent since the start of 2026, illustrating how the combination of operational setbacks, restructuring costs and revised guidance has steadily eroded equity value over the year. More on Evotec stock and restructuring. Further articles on Evotec, its guidance cuts and restructuring program can be found in the Evotec SE topic overview at ad-hoc-news.de. Guidance cut and Project Horizon weigh on sentiment. Evotec's share weakness is closely tied to its restructuring initiative dubbed Project Horizon, which is being financed through a convertible bond placement of EUR 116.1 million, as highlighted in the Ad Hoc News article on the company's shareholder shifts. Recent half-year figures released on August 13, 2026 showed that second-quarter group revenue fell 16.2 percent year on year to EUR 143.5 million, while first-half 2026 revenue declined to EUR 300.1 million compared with EUR 371.0 million in the same period of 2025, underscoring a significant slowdown in the company's top line according to the same Ad Hoc News analysis. Adjusted group EBITDA also deteriorated sharply: Evotec recorded approximately minus EUR 20.8 million in adjusted EBITDA for the second quarter of 2026 and minus EUR 42.7 million for the first six months of 2026, confirming that profitability is under clear pressure even before restructuring costs are fully absorbed. Reflecting these trends, Evotec has cut its full-year 2026 guidance and now expects revenue between EUR 570 million and EUR 610 million alongside adjusted group EBITDA in a range of minus EUR 70 million to minus EUR 105 million, as reported consistently by Ad Hoc News and technology outlet IT Boltwise. An IT Boltwise analysis emphasizes that despite ongoing cost-cutting measures, the revised EBITDA corridor still points to a materially negative result, underlining that the operational turnaround is progressing more slowly than many investors had hoped. Since the publication of the half-year figures and guidance cut in mid-August 2026, Evotec's share price has drifted about 2.4 percent lower, a muted but telling reaction that suggests the market had already priced in much of the bad news and now awaits concrete signs of improvement. Analysts divided on outlook. The cautious tone in the market is reinforced by recent analyst actions: in mid-July 2026, research house TD Cowen downgraded Evotec from buy to hold and assigned a price target of USD 2.00, while HC Wainwright cut its target to USD 4.00 on the same day, according to the Ad Hoc News and IT Boltwise reports. The wide gap between the USD 2.00 and USD 4.00 targets illustrates how divided the analyst community remains about Evotec's future trajectory, with some expecting further downside risk while others still see recovery potential if Project Horizon delivers and guidance stabilizes. Both analyst moves came shortly before the profit warning and guidance reset, effectively serving as early signals that the company's earnings profile for 2026 would be weaker than previously anticipated. Strategic partnerships yet to shift the valuation. To counterbalance the operational pressure, Evotec has pursued new strategic alliances, including a recently announced AI-driven research collaboration with Odyssey Therapeutics focusing on autoimmune and inflammatory diseases, as noted by Ad Hoc News and IT Boltwise. However, roughly one month after this partnership was unveiled, Evotec's share price had slipped by about 5.3 percent, indicating that investors view such scientific collaborations more as long-term portfolio options than immediate catalysts for earnings or cash flow. The combination of a convertible bond-financed restructuring, shrinking revenue, negative adjusted EBITDA and a share price hovering just above its 52-week low means management has limited room for missteps; investors are likely to watch upcoming quarters closely for signs that the cost-saving program and partnership pipeline translate into tangible financial progress. Drug discovery platform as long-term growth driver. Evotec is best known for its integrated drug discovery and development platform, which combines high-throughput screening, medicinal chemistry, translational biology and increasingly AI-supported approaches to help pharmaceutical partners identify and progress new therapeutic candidates. The company generates revenue from discovery alliances, development milestones and potential royalty streams across a broad portfolio of partnered programs, many of which target areas such as oncology, metabolic disease and autoimmune indications. While recent half-year 2026 figures show that short-term revenue and EBITDA are under pressure, Evotec's diversified pipeline and platform-based business model are designed to deliver medium- to long-term growth as successful candidates move through clinical development and into commercialization with partners. Evotec stock price and investor perspective. As of August 30, 2026, Evotec stock closed at EUR 3.37 on Xetra, approximately 5.5 percent above the 52-week low of EUR 3.19 and giving the company a market capitalization of about EUR 597.29 million according to an Ad Hoc News price snapshot; subsequent trading around EUR 3.24 to EUR 3.28 keeps the shares near that floor as of September 1, 2026. Evotec SE stock facts. * Company: Evotec SE * ISIN: DE0005664809 * WKN: 566480 * Ticker: EVT * Trading venue: Xetra * Price (as of August 30, 2026, 16:00): 3.37 EUR * Market capitalization: 597.29 million EUR (as of August 30, 2026) * Sector / Industry: Biotechnology, drug discovery * Index membership: TecDAX Further Evotec insights on social platforms. Sponsored Ad Evotec stock: new analysis - 5 September. Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | DE0005664809 | EVOTEC SE | boerse | 70038284 | bgmi

Evotec (NASDAQ:EVO) issues earnings results. August 13, 2026 Key points. * Evotec missed quarterly expectations: The company reported an adjusted loss of $0.14 per share, versus analysts' expected loss of $0.05, while revenue reached $161.2 million compared with estimates of $173.87 million. The company also reported a negative net margin of 26.2%. * Shares declined amid weak performance: Evotec stock fell $0.17 to $2.02, near its 12-month low of $1.89 and below its 50-day and 200-day moving averages. * Analyst sentiment remains cautious: Recent rating downgrades helped produce a consensus "Hold" rating, with an average price target of $3.00; institutional investors own 5.81% of the stock. * MarketBeat previews the top five stocks to own by September 1st. Evotec (NASDAQ:EVO - Get Free Report) announced its earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.09), FiscalAI reports. Evotec had a negative return on equity of 24.93% and a negative net margin of 26.20%.The company had revenue of $161.20 million for the quarter, compared to analyst estimates of $173.87 million. Evotec price performance. Shares of NASDAQ EVO traded down $0.17 during mid-day trading on Thursday, reaching $2.02. 24,027 shares of the company's stock were exchanged, compared to its average volume of 98,195. Evotec has a twelve month low of $1.89 and a twelve month high of $4.27. The company has a current ratio of 1.68, a quick ratio of 1.60 and a debt-to-equity ratio of 0.43. The business has a fifty day simple moving average of $2.41 and a 200 day simple moving average of $2.82. Wall Street analysts forecast growth. A number of brokerages have recently commented on EVO. Berenberg Bank cut Evotec from a "buy" rating to a "hold" rating in a research note on Thursday, July 16th. Wall Street Zen cut shares of Evotec from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Evotec in a research note on Tuesday, July 21st. TD Cowen lowered shares of Evotec from a "buy" rating to a "hold" rating and set a $2.00 target price on the stock. in a report on Wednesday, July 15th. Finally, HC Wainwright reduced their price target on shares of Evotec from $7.00 to $4.00 and set a "buy" rating on the stock in a research report on Wednesday, July 15th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $3.00. Discover more Dividend screener tool Stock research tools Institutional trading of Evotec. A number of large investors have recently bought and sold shares of EVO. BNP Paribas Financial Markets lifted its stake in Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company's stock valued at $50,000 after buying an additional 4,600 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after buying an additional 9,289 shares during the period. Marshall Wace LLP bought a new stake in shares of Evotec during the fourth quarter worth $40,000. XTX Topco Ltd bought a new stake in shares of Evotec during the second quarter worth $66,000. Finally, HRT Financial LP acquired a new stake in shares of Evotec during the fourth quarter worth $72,000. 5.81% of the stock is owned by institutional investors. About Evotec. Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development. Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Evotec, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list. While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.